BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s share price was down 5.7% during mid-day trading on Monday . The company traded as low as $2.51 and last traded at $2.82, with a volume of 2,405,799 shares. The stock had previously closed at $2.99.

Separately, Maxim Group reissued a “buy” rating and issued a $5.00 price objective on shares of BrainStorm Cell Therapeutics in a report on Monday.

The stock has a 50-day moving average price of $2.50 and a 200 day moving average price of $2.42. The firm’s market capitalization is $48.31 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.15. On average, equities research analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.58) earnings per share for the current fiscal year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.